Puja K Mehta1, Shilpa Sharma2, Margo Minissian2, Manya R Harsch3, Melissa Martinson3, John A Nyman4, Leslee J Shaw5, C Noel Bairey Merz2, Nanette K Wenger1. 1. 1 Division of Cardiology and Emory Women's Heart Center, Emory University School of Medicine, Atlanta, Georgia. 2. 2 Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Los Angeles, California. 3. 3 Technomics Research, Minneapolis, Minnesota. 4. 4 Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota. 5. 5 Department of Radiology, Weil Cornell Medicine, New York, New York.
Abstract
Background: Persistent angina is prevalent in women, who more often present with atypical angina, and experience less relief from antianginal therapies. The impact of ranolazine on female-specific angina is unclear. A single-arm, open-label trial was conducted to quantify the impact of ranolazine on angina in women with ischemic heart disease (IHD). Materials and Methods: Women with IHD and ≥2 angina episodes/week were recruited from 30 U.S. sites. Angina and nitroglycerin (NTG) consumption were assessed using patient-reported diaries, Seattle Angina Questionnaire (SAQ), Duke Activity Score Index (DASI), and Women's Ischemia Symptom Questionnaire (WISQ) at baseline and at 4 weeks of treatment with ranolazine 500 mg twice/day. A modified intent-to-treat analysis and parametric or nonparametric methods were used as appropriate to analyze changes. Results: Of 171 women enrolled, mean age was 65 ± 12 years. Of the 159 women included in the analysis, at week 4 compared to baseline, median angina frequency decreased with ranolazine treatment from 5.0 to 1.5 attacks/week and median change from baseline was -3.3 (95% confidence interval [CI]: -4.0 to -2.5; p ≤ 0.0001). Median NTG consumption decreased from 2.0 to 0.0 per week over the 4 weeks and median change was -1.0 (95% CI: -2.0 to -0.5; p < 0.0001). All five SAQ subscales showed mean improvements: physical limitation 9.2 (standard error [SE] 1.5; p < 0.0001), angina stability 31.8 (SE 2.7; p < 0.0001), angina frequency 17.7 (SE 1.6; p < 0.0001), treatment satisfaction 9.3 (SE 1.6; p < 0.0001), and disease perception 2.9 (SE 0.8; p < 0.0001). DASI score also improved 2.9 (SE 0.8; p = 0.0014). WISQ subscales also showed significant improvements (all p < 0.0001). Thirty-one women reported drug-related adverse events (AEs), predominantly mild to moderate gastrointestinal symptoms. Conclusions: Women with IHD treated with ranolazine for 4 weeks experienced less angina measured by SAQ and WISQ. NTG use decreased, physical activity improved, and treatment satisfaction improved. AEs were consistent with prior reports.
Background: Persistent angina is prevalent in women, who more often present with atypical angina, and experience less relief from antianginal therapies. The impact of ranolazine on female-specific angina is unclear. A single-arm, open-label trial was conducted to quantify the impact of ranolazine on angina in women with ischemic heart disease (IHD). Materials and Methods: Women with IHD and ≥2 angina episodes/week were recruited from 30 U.S. sites. Angina and nitroglycerin (NTG) consumption were assessed using patient-reported diaries, Seattle Angina Questionnaire (SAQ), Duke Activity Score Index (DASI), and Women's Ischemia Symptom Questionnaire (WISQ) at baseline and at 4 weeks of treatment with ranolazine 500 mg twice/day. A modified intent-to-treat analysis and parametric or nonparametric methods were used as appropriate to analyze changes. Results: Of 171 women enrolled, mean age was 65 ± 12 years. Of the 159 women included in the analysis, at week 4 compared to baseline, median angina frequency decreased with ranolazine treatment from 5.0 to 1.5 attacks/week and median change from baseline was -3.3 (95% confidence interval [CI]: -4.0 to -2.5; p ≤ 0.0001). Median NTG consumption decreased from 2.0 to 0.0 per week over the 4 weeks and median change was -1.0 (95% CI: -2.0 to -0.5; p < 0.0001). All five SAQ subscales showed mean improvements: physical limitation 9.2 (standard error [SE] 1.5; p < 0.0001), angina stability 31.8 (SE 2.7; p < 0.0001), angina frequency 17.7 (SE 1.6; p < 0.0001), treatment satisfaction 9.3 (SE 1.6; p < 0.0001), and disease perception 2.9 (SE 0.8; p < 0.0001). DASI score also improved 2.9 (SE 0.8; p = 0.0014). WISQ subscales also showed significant improvements (all p < 0.0001). Thirty-one women reported drug-related adverse events (AEs), predominantly mild to moderate gastrointestinal symptoms. Conclusions: Women with IHD treated with ranolazine for 4 weeks experienced less angina measured by SAQ and WISQ. NTG use decreased, physical activity improved, and treatment satisfaction improved. AEs were consistent with prior reports.
Entities:
Keywords:
and heart disease; angina; ranolazine; women
Authors: Carl J Pepine; Keith C Ferdinand; Leslee J Shaw; Kelly Ann Light-McGroary; Rashmee U Shah; Martha Gulati; Claire Duvernoy; Mary Norine Walsh; C Noel Bairey Merz Journal: J Am Coll Cardiol Date: 2015-10-27 Impact factor: 24.094
Authors: Peter H Stone; Nikolay A Gratsiansky; Alexey Blokhin; I-Zu Huang; Lixin Meng Journal: J Am Coll Cardiol Date: 2006-06-15 Impact factor: 24.094
Authors: M A Hlatky; R E Boineau; M B Higginbotham; K L Lee; D B Mark; R M Califf; F R Cobb; D B Pryor Journal: Am J Cardiol Date: 1989-09-15 Impact factor: 2.778
Authors: Puja K Mehta; Pavel Goykhman; Louise E J Thomson; Chrisandra Shufelt; Janet Wei; Yuching Yang; Edward Gill; Margo Minissian; Leslee J Shaw; Piotr J Slomka; Melissa Slivka; Daniel S Berman; C Noel Bairey Merz Journal: JACC Cardiovasc Imaging Date: 2011-05
Authors: Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Timothy R Wessel; Christopher B Arant; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko Journal: J Am Coll Cardiol Date: 2006-02-07 Impact factor: 24.094
Authors: Marian B Olson; Sheryl F Kelsey; Karen Matthews; Leslee J Shaw; Barry L Sharaf; Gerald M Pohost; Carol E Cornell; Susan P McGorray; Diane Vido; C Noel Bairey Merz Journal: Eur Heart J Date: 2003-08 Impact factor: 29.983
Authors: Bernard R Chaitman; Carl J Pepine; John O Parker; Jaroslav Skopal; Galina Chumakova; Jerzy Kuch; Whedy Wang; Sandra L Skettino; Andrew A Wolff Journal: JAMA Date: 2004-01-21 Impact factor: 56.272
Authors: Vijay Kunadian; Alaide Chieffo; Paolo G Camici; Colin Berry; Javier Escaned; Angela H E M Maas; Eva Prescott; Nicole Karam; Yolande Appelman; Chiara Fraccaro; Gill Louise Buchanan; Stephane Manzo-Silberman; Rasha Al-Lamee; Evelyn Regar; Alexandra Lansky; J Dawn Abbott; Lina Badimon; Dirk J Duncker; Roxana Mehran; Davide Capodanno; Andreas Baumbach Journal: Eur Heart J Date: 2020-10-01 Impact factor: 29.983
Authors: Alexandra Bastiany; Christine Pacheco; Tara Sedlak; Jaqueline Saw; Steven E S Miner; Shuangbo Liu; Andrea Lavoie; Daniel H Kim; Martha Gulati; Michelle M Graham Journal: CJC Open Date: 2022-05-04